News | February 24, 2022
Sanofi and GSK to seek regulatory authorization for Covid-19 vaccine
100% efficacy against severe Covid-19 disease and hospitalizations
100% efficacy against severe Covid-19 disease and hospitalizations
The first wave of shipments includes several countries, such as Germany, France and Austria
Essential products manufactured by Sartorius, using Sü dpack polymer films made from Dow resins, support safe and effective vaccine production for global vaccine supply
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
The grants are expected to be received over the next three years, commencing March 2022
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia
Apexxnar is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible for the majority of invasive disease and pneumococcal pneumonia
Monitoring results demonstrated a good safety profile of the combination. No serious adverse events related to vaccination were registered
Subscribe To Our Newsletter & Stay Updated
